Trial · NCT01945021
Adverse events111
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
81 to 100 of 111
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Headache | Nervous system disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Ruptured cerebral aneurysm | Nervous system disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Seizure | Nervous system disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Renal cyst | Renal and urinary disorders | Crizotinib 250 mg | 2 | 127 | |
| serious | Pleural effusion | Respiratory, thoracic and mediastinal disorders | Crizotinib 250 mg | 3 | 127 | |
| serious | Respiratory failure | Respiratory, thoracic and mediastinal disorders | Crizotinib 250 mg | 5 | 127 | |
| serious | Pneumothorax | Respiratory, thoracic and mediastinal disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Deep vein thrombosis | Vascular disorders | Crizotinib 250 mg | 2 | 127 | |
| serious | Embolism | Vascular disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Anaemia | Blood and lymphatic system disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Bradycardia | Cardiac disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Retinal detachment | Eye disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Chronic gastritis | Gastrointestinal disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Hernia | General disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Peripheral swelling | General disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Drug-induced liver injury | Hepatobiliary disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Liver injury | Hepatobiliary disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Postoperative wound infection | Infections and infestations | Crizotinib 250 mg | 1 | 127 | |
| serious | Renal tuberculosis | Infections and infestations | Crizotinib 250 mg | 1 | 127 | |
| serious | Tuberculosis | Infections and infestations | Crizotinib 250 mg | 1 | 127 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01945021/events?page=5